PMID- 16132580
OWN - NLM
STAT- MEDLINE
DCOM- 20051018
LR  - 20220318
IS  - 0262-0898 (Print)
IS  - 0262-0898 (Linking)
VI  - 22
IP  - 1
DP  - 2005
TI  - Selective antimetastatic effect of heparins in preclinical human melanoma models 
      is based on inhibition of migration and microvascular arrest.
PG  - 69-76
AB  - Use of heparin derivatives in several cancer types revealed that anticoagulant 
      therapies have a beneficiary side effect: delay of tumor progression. Since there 
      are no data on human melanoma, we have analyzed the effect of heparins in 
      preclinical models. Neither unfractionated heparin (UFH), nor its low molecular 
      weight derivative (LMWH) influenced in vitro or in vivo growth of HT168-M1 human 
      melanoma cells. However, heparins significantly inhibited lung colony formation 
      and liver metastasis development in the concentration range of 20-200 IU/kg, 
      whereas recombinant hirudin was ineffective. The antimetastatic effect was due to 
      an early (5-60 min) inhibition of tumor cell arrest in the lung microvasculature. 
      Analysis of the molecular mechanism of the antimetastatic effect of heparins 
      indicated a specific inhibition of tumor cell migration and matrix invasion. The 
      presented experimental data suggest that heparins have specific antimetastatic 
      effect in the case of human melanoma, which is independent from the coagulation 
      cascade.
FAU - Bereczky, Biborka
AU  - Bereczky B
AD  - Department of Tumor Progression, National Institute of Oncology, Rath Gy. u. 7-9, 
      Budapest, 1122 Hungary.
FAU - Gilly, Reka
AU  - Gilly R
FAU - Raso, Erzsebet
AU  - Raso E
FAU - Vago, Agnes
AU  - Vago A
FAU - Timar, Jozsef
AU  - Timar J
FAU - Tovari, Jozsef
AU  - Tovari J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Clin Exp Metastasis
JT  - Clinical & experimental metastasis
JID - 8409970
RN  - 0 (Anticoagulants)
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Capillaries/drug effects
MH  - Cell Proliferation/drug effects
MH  - Extracellular Matrix Proteins/metabolism
MH  - Female
MH  - Hemostasis/drug effects
MH  - Heparin/pharmacology/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/pharmacology/therapeutic use
MH  - Humans
MH  - Liver Neoplasms/blood supply/*prevention & control/*secondary
MH  - Lung Neoplasms/blood supply/*prevention & control/*secondary
MH  - Melanoma/*drug therapy/*pathology
MH  - Mice
MH  - Mice, SCID
MH  - Neoplasm Transplantation
MH  - Neoplastic Stem Cells/drug effects/metabolism
MH  - Tumor Cells, Cultured
EDAT- 2005/09/01 09:00
MHDA- 2005/10/19 09:00
CRDT- 2005/09/01 09:00
PHST- 2004/11/16 00:00 [received]
PHST- 2005/03/14 00:00 [accepted]
PHST- 2005/09/01 09:00 [pubmed]
PHST- 2005/10/19 09:00 [medline]
PHST- 2005/09/01 09:00 [entrez]
AID - 10.1007/s10585-005-3859-6 [doi]
PST - ppublish
SO  - Clin Exp Metastasis. 2005;22(1):69-76. doi: 10.1007/s10585-005-3859-6.